CLOs on the Move

Center For Innovation Inc

www.cfi-mt.com

 
Center For Innovation Inc is a Butte, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cfi-mt.com
  • 305 W Mercury St
    Butte, MT USA 59701
  • Phone: 406.782.9800

Executives

Name Title Contact Details

Similar Companies

ECHO

Discover Echo redefines traditional microscope design. Experience our award-winning Automated, Fluorescence, and Transmitted Light Microscopes.

CellzDirect Inc

CellzDirect Inc is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Marine Desalination Systems, L.L

Marine Desalination Systems, L.L is a Saint Petersburg, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Camurus

Camurus is a Swedish science-led biopharmaceutical company committed to improving the lives of patients with severe and chronic diseases. We empower patients, support caregivers and create value for society by developing and giving access to innovative, long-acting medicines. To fulfill our commitment, we are determined to conduct our business in a sustainable manner. New drug products with best-in-class potential are conceived based on the companys proprietary FluidCrystal® technology and extensive R&D expertise. Camurus clinical pipeline includes products for the treatment of treatment of opioid dependence, cancer, and endocrine disorders, which are developed in-house and in collaboration with international pharmaceutical companies. The companys shares are listed on Nasdaq Stockholm under the ticker CAMX.

Oxford Immunotec

Oxford Immunotec is a global, commercial-stage diagnostics company committed to improving patient care by providing advanced, innovative tests in the field of immunology. Our proprietary   T-SPOT technology platform allows us to measure the responses of specific immune cells, known as T cells, to inform the diagnosis, prognosis and monitoring of patients with immunologically controlled diseases.   The initial product we have developed using our T-SPOT technology platform is our T-SPOT.TB test, which is used to test for latent Tuberculosis (TB) infection, or LTBI. Our T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where we have received pre-market approval (PMA) from the Food and Drug Administration (FDA), in Europe, where we have obtained a CE mark, as well as Japan and China. Our T-SPOT.TB test has been included in clinical guidelines (that is, guidelines issued by governmental agencies and professional societies covering recommended or suggested uses of available diagnostics) for TB screening in 17 countries, including the United States, several European countries and Japan.   We are a publicly traded company listed in the United States on the NASDAQ stock exchange (NASDAQ:OXFD).